InvestorsHub Logo
Followers 0
Posts 74
Boards Moderated 0
Alias Born 03/18/2018

Re: None

Wednesday, 08/08/2018 1:26:27 PM

Wednesday, August 08, 2018 1:26:27 PM

Post# of 18784
CEO Matthew Paul of Strongbridge Biopharma (licensee of Macrilen in the USA and Canada) said that he is delighted with the sales launch of Macrilen last month and that the price of Macrilen is DOUBLE the price that it was originally anticipated to be. The cost of Macrilen is $4500 per unit. CEO Matthew Paul said that Macrilen expanded growth market could be BIG in the traumatic brain injury (TBI) area. Around an estimated 700,000 eligible TBI patients per year.https://edge.media-server.com/m6/p/9ypi6z33
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AEZS News